Review article: from gastrin to gastro-oesophageal reflux disease--a century of acid suppression
- PMID: 16556170
- DOI: 10.1111/j.1365-2036.2006.02817.x
Review article: from gastrin to gastro-oesophageal reflux disease--a century of acid suppression
Abstract
To commemorate Edkins' discovery of gastrin in 1905, we review a century of progress in the physiology and pathobiology of gastrin and acid secretion especially as it pertains to clinical aspects of gastro-oesophageal reflux disease. Although initially ignored, Edkins' observations eventually led to the enthusiastic investigation of gastrin and acid regulation in peptic ulcer disease, culminating in important therapeutic advances in the management of acid peptic disease. Following the improved understanding of gastric secretory physiology, and the development of acid suppressants with increasing efficacy, the use of surgical intervention for peptic ulcer disease was almost eliminated. Surgery became obsolete with the discovery of Helicobacter pylori. Three other advances are also influencing modern practice: the gastrotoxicity of aspirin and non-steroidal anti-inflammatory drugs is now increasingly appreciated, the role of endoscopy in the diagnosis and therapy of upper gastrointestinal bleeding, and the use of intravenous acid-suppressive agents. The major issue for the future resides within the epidemic of gastro-oesophageal reflux disease. How to diagnose, categorize and treat this condition and how to identify and prevent neoplasia, are the challenges of the new century.
Similar articles
-
Helicobacter pylori and its involvement in gastritis and peptic ulcer formation.J Physiol Pharmacol. 2006 Sep;57 Suppl 3:29-50. J Physiol Pharmacol. 2006. PMID: 17033104 Review.
-
[Chemotherapy and NSAIDs in neoplastic disease. Role of anti-secretory preventive therapy].Recenti Prog Med. 2003 Nov;94(11):473-7. Recenti Prog Med. 2003. PMID: 14679914 Review. Italian.
-
Review article: Helicobacter pylori and gastro-oesophageal reflux disease.Aliment Pharmacol Ther. 2005 Aug;22 Suppl 1:32-40. doi: 10.1111/j.1365-2036.2005.02607.x. Aliment Pharmacol Ther. 2005. PMID: 16042657 Review.
-
Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.Aliment Pharmacol Ther. 2004 Nov;20 Suppl 6:1-10. doi: 10.1111/j.1365-2036.2004.02160.x. Aliment Pharmacol Ther. 2004. PMID: 15496213 Review.
-
[Gastric and duodenal ulcers--etiopathogenesis, diagnosis and therapy at the milestone of the 20th century].Vnitr Lek. 2004 Oct;50 Suppl 1:S91-3. Vnitr Lek. 2004. PMID: 15651149 Czech.
Cited by
-
Clinical Implications of Proton Pump Inhibitors and Vonoprazan Micro/Nano Drug Delivery Systems for Gastric Acid-Related Disorders and Imaging.Nanotheranostics. 2024 Sep 30;8(4):535-560. doi: 10.7150/ntno.100727. eCollection 2024. Nanotheranostics. 2024. PMID: 39507107 Free PMC article. Review.
-
Efficacy of alfacalcidol and alendronate on lumbar bone mineral density in osteoporotic patients using proton pump inhibitors.Biomed Rep. 2016 Aug;5(2):165-170. doi: 10.3892/br.2016.710. Epub 2016 Jun 30. Biomed Rep. 2016. PMID: 27446535 Free PMC article.
-
Impact of PPIs on patient focused symptomatology in GERD.Ther Clin Risk Manag. 2008 Dec;4(6):1185-200. doi: 10.2147/tcrm.s3132. Ther Clin Risk Manag. 2008. PMID: 19337426 Free PMC article.
-
Eosinophilic esophagitis in patients with typical gastroesophageal reflux disease symptoms refractory to proton pump inhibitor.Clinics (Sao Paulo). 2011;66(4):557-61. doi: 10.1590/s1807-59322011000400006. Clinics (Sao Paulo). 2011. PMID: 21655746 Free PMC article.
-
Acid peptic diseases: pharmacological approach to treatment.Expert Rev Clin Pharmacol. 2009 May;2(3):295-314. doi: 10.1586/ecp.09.8. Expert Rev Clin Pharmacol. 2009. PMID: 21822447 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical